NCT03883295

Brief Summary

Total amputation therapy; is a treatment method aimed at maintaining the vitality of the radicular pulp remaining as a result of complete removal of coronal pulp tissue. In cases where pulp is exposed due to caries or trauma, the pulp is vital, bleeding can be controlled during the procedure, no periapical pathology is seen and radicular pulp is healthy. Traditionally, acute pulp pain is thought to be a symptom of irreversible pulpitis, and it is thought that there is little chance of the pulp returning to its normal situation after removal of the irritants. Root canal treatment has been accepted as the gold standard for the treatment of these symptoms. In recent studies, spontaneous or severe pain before procedure has not always indicated that pulp has no repair capacity, and deep carious lesions are not necessarily associated with irreversible pulpal pathology. Histological studies showed that even when caries reach the pulp or degeneration and inflammation were seen in it, there was a healthy section still present in the pulp. Therefore, it is stated that the healthy pulp remaining as a result of total amputation performed by removal of degenerated pulp can be preserved. Furthermore, it is stated that for the healing potential of the remaining pulp tissue, the original signal should be that the bleeding can be controlled after the amputation of the infected pulp tissue. While the most popular method in the treatment of vital pulp is CaOH, the American Academy of Pediatric Dentistry has been reported to be more resistant to dissolution in the protocol in recent years. MTA is a more suitable material because it is more homogeneous, and forms a thicker dentin bridge. However, the MTA requires a long time to harden, it is difficult to manipulate and color. In recent years, researchers have focused on creating new MTA formulations to improve their physicochemical properties without affecting their biocompatibility and bioactivity. NeoMTA Plus is a new fine powder tricalcium silicate. It consists of a water-based gel and powder mixture and the powder-gel mixing ratio may vary depending on the area of use. It is a material similar to MTA Plus. However, in order to avoid tooth discoloration, tantalium oxide used instead of the bismuth oxide and required calcium hydroxide used to induce the formation of mineralized tissue.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2018

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2018

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

March 18, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 20, 2019

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2019

Completed
16 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2019

Completed
Last Updated

March 25, 2019

Status Verified

March 1, 2019

Enrollment Period

1.1 years

First QC Date

March 18, 2019

Last Update Submit

March 22, 2019

Conditions

Outcome Measures

Primary Outcomes (3)

  • Postoperative pain

    Using visual analogue scale by participant. It is usually presented as a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable". The scale has no other subscales.

    12 months

  • Pulp sensibility

    Using cold and electric pulp testings by clinicians

    12 months

  • Radiological evaluation

    Standardized periapical radiographs will be taken and monitored

    12 months

Study Arms (2)

Control

EXPERIMENTAL

root canal treatment will be initiated

Procedure: Control

NeoMTA Plus

EXPERIMENTAL

vital pulp treatment using neomta plus will be used.

Procedure: NeoMTA Plus

Interventions

ControlPROCEDURE

The specimens will be root canal treated conventionally

Also known as: Conventional root canal treatment
Control
NeoMTA PlusPROCEDURE

The specimens will be subjected to vital pulp amputation using NeoMTA Plus.

Also known as: Pulp amputation
NeoMTA Plus

Eligibility Criteria

Age8 Years - 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Having a lower molar and lower/upper premolars diagnosed with irreversible pulpitis

You may not qualify if:

  • Patients with systemic disease
  • Negative outcome of pulp sensibility
  • Patients presenting abscess

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Elif Kalyoncuoğlu

Samsun, 55139, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

PulpitisDental Pulp Diseases

Condition Hierarchy (Ancestors)

Tooth DiseasesStomatognathic Diseases

Study Officials

  • Ayça T Ulusoy Yamak

    ONDOKUZ MAYIS UNIVERSITY, FACULTY OF DENTISTRY DEPARTMENT OF PEDIATRIC DENTISTRY

    PRINCIPAL INVESTIGATOR

Central Study Contacts

ELİF KALYONCUOĞLU, Phd

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc.Prof

Study Record Dates

First Submitted

March 18, 2019

First Posted

March 20, 2019

Study Start

November 1, 2018

Primary Completion

December 15, 2019

Study Completion

December 31, 2019

Last Updated

March 25, 2019

Record last verified: 2019-03

Data Sharing

IPD Sharing
Will not share

Locations